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Introduction {#sec1}
============

Macrophages are central in orchestrating host responses to tissue injury and infections ([@bib18], [@bib20], [@bib31]). The biological actions of these cells are associated with their phenotype, where classically activated macrophages are central in the initiation and propagation of the inflammatory response, whereas alternatively activated macrophages orchestrate tissue repair and regeneration ([@bib10], [@bib20], [@bib26]). Investigations into the cellular mechanisms underlying these distinct biological functions demonstrate that each macrophage subtype produces a characteristic repertoire of bioactive molecules, including cytokines and lipid mediators (LMs) ([@bib10], [@bib20]). In this context, recent studies demonstrate that, while classically activated macrophages and alternatively activated macrophages produce both inflammation initiating eicosanoids and pro-resolving mediators, their LM phenotypes differ. Indeed, classically activated macrophages produce higher amounts of pro-inflammatory eicosanoids, whereas alternatively activated macrophages produce higher levels of the recently identified specialized pro-resolving mediators (SPMs) ([@bib11]). Tissue macrophages arise during either embryonic development or are differentiated *in situ* from monocyte precursors ([@bib23]). Mechanisms that dictate monocyte differentiation to different macrophage phenotypes are of relevance in determining whether inflammation is perpetuated or resolves, thus permitting regain of function.

SPMs are produced via the stereoselective conversion of essential fatty acids. The first SPMs identified were the lipoxins (LX) that are produced from arachidonic acid and carry potent leukocyte directed actions ([@bib38]). The D-series resolvins (RvD) produced from docosahexaenoic acid (DHA) and the E-series resolvins (RvE) produced from eicosapentaenoic acid also display leukocyte-directed actions ([@bib5]). In addition, RvEs regulate platelet response ([@bib15]) and neutrophil apoptosis ([@bib16]), while the RvDs regulate vascular smooth muscle cell migration, a key process in the development of intimal hyperplasia ([@bib27]). Recently, we found that n-3 docosapentaenoic acid (DPA) is also a substrate for conversion to a new series of pro-resolving mediators, which include the n-3 DPA-derived protectins (PD~n-3\ DPA~) ([@bib9]). These mediators were initially identified in self-limited inflammatory exudates, with their production coinciding with monocyte/macrophage trafficking to the site. Human primary macrophages also produce these mediators. Of note, PD1~n-3\ DPA~ and PD2~n-3\ DPA~ carry potent leukocyte directed actions, reducing neutrophil recruitment as well as the production of inflammatory cytokines, including monocyte chemoattractant protein-1, during sterile inflammation ([@bib9]). These actions were also found with human primary cells, where PD~n-3\ DPA~ reduce human neutrophil-endothelial cell interactions, neutrophil chemotaxis, and increased macrophage phagocytosis. The complete stereochemistry of the first member of this family of mediators, PD1~n-3 DPA~, was recently established as 10*R*,17*S*-dihydroxydocosa-7*Z*,11*E*,13*E*,15*Z*,19*Z*-pentaenoic acid ([@bib2]). In humans, PD1~n-3\ DPA~ is upregulated in colon samples from IBD patients and displays potent tissue protective actions in mice during experimental colitis, reducing leukocyte-mediated tissue damage ([@bib19]).

The PD~n-3\ DPA~ biosynthetic pathway in human monocytes and macrophages is proposed to be initiated by 15-lipoxygenases (LOX), which convert n-3 DPA to an intermediate epoxide that in turn is enzymatically hydrolyzed to PD1~n-3\ DPA~ ([@bib2]) and PD2~n-3\ DPA~ (16,17*R*-dihydroxy-7*Z*,10,13,14,19*Z*-docosapentaenoic acid) ([@bib9]). Given the potent biological actions of PD~n-3\ DPA~, and the central role of the proposed epoxide intermediate in the formation of these pro-resolving mediators, it was deemed important to (1) obtain evidence for its formation and role in the PD~n-3\ DPA~ biosynthesis, (2) establish the identity of enzyme(s) involved in the formation of this epoxide in human monocytes/macrophages, and (3) establish the biological actions of the PD~n-3\ DPA~ pathway in monocyte differentiation and macrophage responses. Using acid alcohol trapping, recombinant enzymes and human primary cells we found that both ALOX15 and ALOX15B catalyze the formation of 16,17*S*-ePD~n-3\ DPA~. Using total organic synthesis we obtained stereochemically pure material, that, when incubated with primary human macrophages, was converted to both PD1~n-3\ DPA~ and PD2~n-3\ DPA~. Furthermore, we found that the PD~n-3\ DPA~ pathway was important in regulating macrophage phenotype and function.

Results {#sec2}
=======

Inhibition of 15-Lipoxygenase Activity in Human Monocytes Reduced Macrophage PD~n-3\ DPA~ Metabolome and Altered Macrophage Function {#sec2.1}
------------------------------------------------------------------------------------------------------------------------------------

To obtain evidence for the role of the PD~n-3\ DPA~ biosynthetic pathway in regulating human macrophage function during monocyte differentiation, we incubated monocytes with an ALOX15 inhibitor and assessed the production of components within the PD~n-3\ DPA~ pathway. In human primary cells, using liquid chromatography-tandem mass spectrometry (LC/MS-MS), we identified 17-HDPA, PD1~n-3\ DPA~, and PD2 ~n-3\ DPA~. In these incubations we also identified 10*R/S*,17*S*-diHDPA and 16*R/S*,17*S*-diHDPA, which correspond to the non-enzymatic products of the proposed epoxide intermediate in the PD~n-3\ DPA~ pathway ([Figure 1](#fig1){ref-type="fig"}A). Of note, incubation of monocytes with an inhibitor of ALOX15 led to a significant reduction in all the components of the PD~n-3\ DPA~ biosynthetic pathway, including the bioactive mediators PD1~n-3\ DPA~ and PD2~n-3\ DPA~ ([Figure 1](#fig1){ref-type="fig"}A; [Table S1](#mmc1){ref-type="supplementary-material"}). The role of 15-lipoxygenases in PD~n-3\ DPA~ biosynthesis was further corroborated using cells from mice deficient in the murine homolog of this enzyme (ALOX15^−/−^), which demonstrated a significant reduction in all the components within the PD~n-3\ DPA~ pathway ([Figure S1](#mmc1){ref-type="supplementary-material"}; [Table S2](#mmc1){ref-type="supplementary-material"}).Figure 1Inhibiting 15-Lipoxygenase Activity Reduces PD~n-3\ DPA~ Production Dysregulating Macrophage Phenotype and Function(A) Human monocytes were incubated with M-CSF (20 ng/mL) and either a ALOX15 inhibitor or vehicle (37°C, 5% CO~2~). On day 7 incubations were quenched, lipid mediators were extracted, identified, and quantified using lipid mediator profiling (see the [STAR Methods](#sec5){ref-type="sec"} for details). Results are mean ± SEM. n = 6 donors. \*p \< 0.05.(B) Human monocytes were isolated and incubated with GM-CSF (20 ng/mL), IFN-γ (20 ng/mL), and LPS (100 ng/mL) to produce M1 or M-CSF (20 ng/mL) and IL-4 (20 ng/mL) to obtain M2 cells, and the expression of ALOX15 and ALOX15B was evaluated during the differentiation time course using flow cytometry. Results are mean ± SEM n = 4--6 donors per interval.(C and D) Human monocytes were incubated with vehicle or ALOX15 inhibitor and then with M-CSF (20 ng/mL) for 7 days, and (C) expression of lineage markers was determined using fluorescently labeled antibodies and flow cytometry on day 7, and interrogated using OPLS-DA. n = 6 donors. (D) Phagocytosis of fluorescently labeled apoptotic cells investigated. Results for are mean ± SEM. n = 6 donors. \*p \< 0.05.(E) Peritoneal macrophages were harvested from wild-type (WT) and ALOX15^−/−^ mice, and the expression of lineage markers on CD64^+^ cells was determined using flow cytometry. Results were interrogated using OPLS-DA and are representative of n = 7 mice.(F) Fluorescently labeled apoptotic cells were administered to WT and ALOX15^−/−^ mice via intraperitoneal injection. After 1 hr peritoneal cells were harvested, and phagocytosis of apoptotic cells by CD64^+^ cells was evaluated using flow cytometry. Results are mean ± SEM. n = 7 mice per group. \*p \< 0.05.Related to [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"} and [Tables S1--S3](#mmc1){ref-type="supplementary-material"}.

Human leukocytes express two ALOX15 subtypes, therefore we sought to determine the temporal regulation of these enzymes in circulating monocytes and during monocyte-macrophage differentiation. Flow cytometric analysis demonstrated that human circulating monocytes express both ALOX15 and ALOX15B. The expression of both enzyme isoforms was upregulated during monocyte-to-macrophage differentiation. Of note, ALOX15 expression was higher in M2 differentiated cells, whereas the expression of ALOX15B was higher in M1 cells ([Figure 1](#fig1){ref-type="fig"}B). We next investigated the contribution of each of these two enzymes to PD~n-3\ DPA~ biosynthesis in human monocytes. Here we found that transfection of human monocytes with short hairpin RNA (shRNA) to ALOX15 reduced enzyme expression by ∼50% (p \< 0.05; n = 5 donors), and the concentrations of several components of the PD~n-3\ DPA~ biosynthetic pathway, including PD1~n-3\ DPA~ and PD2~n-3\ DPA~. Transfection of monocytes with shRNA to ALOX15B significantly reduced both enzyme expression (∼50%; p \< 0.05; n = 5 donors) and PD~n-3\ DPA~ concentrations, albeit to a lesser extent than observed with shRNA to ALOX15 ([Figure S2](#mmc1){ref-type="supplementary-material"}).

Given that PD1~n-3\ DPA~ and PD2~n-3\ DPA~ carry potent biological actions, we next questioned whether inhibition of this pathway during monocyte-to-macrophage differentiation influenced macrophage phenotype and function. We therefore assessed the expression of phagocytic receptors and adhesion molecules, which are linked with macrophage phenotype. Incubation of cells with ALOX15 inhibitor during monocyte differentiation led to the downregulation of several lineage markers, including CD206, CD163, and CD64, and a shift in macrophage phenotype ([Figure 1](#fig1){ref-type="fig"}C). This downregulation in phagocytic receptors was of functional consequence since inhibition of the PD~n-3\ DPA~ biosynthetic pathway also significantly downregulated the ability of human macrophages to uptake apoptotic cells ([Figure 1](#fig1){ref-type="fig"}D), a key pro-resolving action ([@bib5], [@bib10]). This alteration in macrophage phenotype and function was also observed in tissue-resident macrophages from ALOX15-deficient animals. In these mice the expression of lineage markers on splenic macrophages, small peritoneal macrophages, and large peritoneal macrophages was altered with a downregulation in the expression of several markers including transforming growth factor β and T-cell immunoglubulin and mucin domain containing protein (TIM)-4 ([Figure 1](#fig1){ref-type="fig"}E). This was associated with a decreased ability of peritoneal macrophages to uptake apoptotic cells *in vivo* ([Figure 1](#fig1){ref-type="fig"}F; [Table S3](#mmc1){ref-type="supplementary-material"}).

Having established a role of the PD~n-3\ DPA~ metabolome in regulating human macrophage function we next sought to obtain further evidence for the PD~n-3\ DPA~ biosynthetic pathway. Given the central role that the proposed 16,17*S*-ePD~n-3\ DPA~ plays in the biosynthesis of PD~n-3\ DPA~, we sought to gain evidence for the formation of the proposed epoxide in human monocytes. For this purpose we assessed the formation of the epoxide using acid alcohol trapping, given that allylic epoxides are known to be unstable in aqueous solutions ([@bib34]). Using LC/MS-MS we identified four peaks, the first two gave a retention time (T~R~) and MS-MS fragmentation spectra corresponding with 10-methoxy,17*S*-hydroxy-docosapentaenoic acid ([Figure 2](#fig2){ref-type="fig"}A), whereas, the T~R~ and MS-MS spectra for peaks III and IV corresponded to 16-methoxy,17*S*-hydroxy-docosapentaenoic acid ([Figure 2](#fig2){ref-type="fig"}A).Figure 2Human ALOX15 and Monocytes Produces a Novel 16,17*S*-ePD~n-3\ DPA~(A--C) Human monocytes (1 × 10^8^ cells/mL; PBS; 37°C) (A), hr-ALOX15 (0.2 μM, 37°C \[pH 8\]) (B), and hr-ALOX15B (0.2 μM, 37°C \[pH 8\]) (C) were incubated with n-3 DPA (10 μM). After 3 min, incubations were quenched using acidified methanol, products extracted and identified using lipid mediator profiling. Left panels: MRM chromatogram for ion pairs *m/z* 375 \> 277. Middle and right panels: MS-MS spectra employed in the identification of (middle panel) 10-methoxy,17*S*-hydroxy-7*Z*,11*E*,13*E*,15*E*,19Z-docosapentaenoic acid, (right panel) 16-methoxy,17*S*-hydroxy-7*Z*,10*Z*,12*E*,14*E*,19*Z*-docosapentaenoic acid in monocyte incubations. Results are representative of n = 4 donors and three independent experiments. Related to [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

Having obtained evidence for the formation of an epoxide intermediate by human monocytes we sought to determine whether ALOX15 enzymes were responsible for the formation of this intermediate. For this purpose we incubated human recombinant (hr) ALOX15 and hr-ALOX15B with n-3 DPA and assessed the acid alcohol trapping products using LC/MS-MS. This also gave four peaks that displayed essentially identical T~R~ and MS-MS fragmentation spectra to the products obtained with primary human macrophages ([Figures 2](#fig2){ref-type="fig"}B and 2C). Thus, these results establish the role of human ALOX15 enzymes in the formation of 16,17*S*-ePD~n-3\ DPA~.

Establishing the Complete Stereochemistry of 16*S*,17*S*-ePD~n-3\ DPA~ {#sec2.2}
----------------------------------------------------------------------

Having obtained evidence for the formation of 16,17*S*-ePD~n-3\ DPA~ by human monocytes and the role of ALOX15 enzymes in its production, we next sought evidence for its role in the biosynthesis of PD1~n-3\ DPA~ and PD2~n-3\ DPA~. For this purpose we obtained stereochemically pure material using total organic synthesis. The methyl ester of 16*S*,17*S*-ePD~n-3\ DPA~ was constructed via two key precursors ([Figure 3](#fig3){ref-type="fig"}A). These precursors were obtained using the following stereoselective reactions: a Katsuki-Sharpless epoxidation protocol ([@bib24]) and one *Z*- and two *E*-selective Wittig reactions ([@bib25]). The detailed description of the synthetic route is reported in [@bib32]. The chemical purity and stereochemical integrity was validated using LC/MS-MS and nuclear magnetic resonance (NMR). The unambiguous assignment of the geometrical configurations of the olefins constituting the *E,E,Z*-triene moiety was performed using a ^1^H-^1^H COSY-45 NMR experiment ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}). The following chemical shifts and coupling constants (*J* values) were recorded for the epoxy methyl ester of 16*S*,17*S*-ePD~n-3\ DPA~: H~12~: 6.54 ppm, *J* = 14.7, 11.4 Hz; H~14~: 6.39 ppm, *J* = 15.3, 10.8 Hz; H~13~: 6.11 ppm, *J* = 14.8, 10.9 Hz; H~11~: 6.04 ppm, *J* = 11.2 Hz; H~10~ and H~15~: 5.48--5.32 ppm. Notably, H~11~ has a ^3^*J*-coupling constant to H~10~ with a value of 11.2 Hz, which is consistent with the assigned *Z*-rather than an *E*-configured C10-C11 double bond. The UV chromophore of this compound was also consistent with that of an allylic epoxide conjugated to a triene double-bond system, giving a λ~max~^MeOH^ of 280 nm with shoulders at 271 and 298 nm. These results confirm the stereochemistry of the synthetic epoxide as 16*S*,17*S*-epoxy-7*Z*,10*Z*,12*E*,14*E*,19*Z*-docosapentaenoic acid methyl ester.Figure 3Total Organic Synthesis of 16,17*S*-ePD~n-3\ DPA~(A) Outline of the synthetic strategy and key precursors employed in the preparation of 16*S*,17*S*-ePD~n-3\ DPA~.(B) *Z* and *E* stereochemical assignment for C=C using two-dimensional NMR spectroscopy. Contours denote positive and negative contours.Related to [Figures S3](#mmc1){ref-type="supplementary-material"}.

We next assessed whether the physical properties of the synthetic material obtained after lenient hydrolysis of the epoxy methyl ester matched those of the biological material. Incubation of the synthetic material in acid alcohol gave four distinct peaks with products displaying essentially identical T~R~ and MS-MS fragmentation spectra as those obtained with hr-ALOX15 enzymes and human monocytes ([Figures 2](#fig2){ref-type="fig"} and [S4](#mmc1){ref-type="supplementary-material"}).

We next investigated whether the synthetic material was substrate for conversion to PD1~n-3\ DPA~ and PD2~n-3\ DPA~. To this end, human macrophages were incubated with 16*S*,17*S*-ePD~n-3\ DPA~ and products were assessed using LC/MS-MS. In multiple reaction monitoring (MRM) we obtained two peaks. The first peak eluted with a T~R~ of 13.8 min and gave characteristic fragments in the MS-MS that are consistent with PD1~n-3\ DPA.~ These fragments included the following diagnostic ions: *m/z* 361, *m/z* 183, and *m/z* 155 ([Figures 4](#fig4){ref-type="fig"}A and 4B). The second peak eluted with a T~R~ of 15.2 min and gave ions in the MS-MS that were characteristic of PD2~n-3\ DPA~ including: *m/z* 361, *m/z* 263, and *m/z* 233 ([Figures 4](#fig4){ref-type="fig"}A and 4C). Of note, incubation of 16*S*,17*S*-ePD~n-3\ DPA~ in PBS only or with cells that had been previously kept at 100°C did not yield notable levels of these mediators ([Figure 4](#fig4){ref-type="fig"}D), indicating that the conversion of the epoxide to PD1~n-3\ DPA~ and PD2~n-3\ DPA~ was reliant on enzyme-mediated catalysis. In addition, these results establish the stereochemistry of the allylic epoxide intermediate as 16*S*,17*S*-epoxy-7*Z*,10*Z*,12*E*,14*E*,19*Z*-docosapentaenoic acid.Figure 416*S*,17*S*-ePD~n-3\ DPA~ Is Precursor to PD1~n-3\ DPA~ and PD2~n-3\ DPA~16*S*,17*S*-ePD~n-3\ DPA~ (10 nM) was incubated with human macrophages (MΦ; 4 × 10^7^ cells/mL) or inactivated human macrophages (i.e., 4 × 10^7^ cells/mL previously been kept at 100°C for 1h). *E. coli* (2.5 × 10^8^ colony-forming units \[CFU\]/mL) were added, cells incubated for 15 min, at 37°C, and incubations were quenched using ice-cold methanol. Products were then extracted and profiled using lipid mediator profiling. Vehicle denotes solution containing 0.1% EtOH in PBS.(A) MRM chromatogram for PD1~n-3\ DPA~ (*m/z* 361 \> 183) and PD2~n-3\ DPA~ (*m/z* 361 \> 233).(B and C) MS-MS spectra employed for identification of (B) PD1~n-3\ DPA~ (C) PD2~n-3\ DPA~.(D) PD1~n-3\ DPA~ and PD2~n-3\ DPA~ concentrations. Results are representative of n = 4 donors from two independent experiments. Results are means ± SEM. \*\*p \< 0.001, \*\*\*p \< 0.0001 versus vehicle incubations. \$p \< 0.05 versus MΦ + *E. coli* incubations.

Epoxide Hydrolases Convert 16*S*,17*S*-ePD~n-3\ DPA~ to PD1~n-3\ DPA~ and PD2~n-3\ DPA~ {#sec2.3}
---------------------------------------------------------------------------------------

Having established a role for enzymes in catalyzing the conversion of 16*S*,17*S*-ePD~n-3\ DPA~ to PD1~n-3\ DPA~ and PD2~n-3\ DPA~ we next sought to establish the identity of these enzymes. Given the role that epoxide hydrolases play in converting allylic epoxides to bioactive mediators we assessed whether this class of enzymes was also involved in catalyzing the conversion of 16*S*,17*S*-ePD~n-3\ DPA~ in human monocytes. Incubation of human macrophages with the epoxide hydrolase inhibitor AUDA led to a reduction in the concentrations of both PD1~n-3\ DPA~ and PD2~n-3\ DPA~ ([Figure 5](#fig5){ref-type="fig"}A).Figure 5Epoxide Hydrolases Convert 16*S*,17*S*-ePD~n-3\ DPA~ to PD1~n-3\ DPA~ and PD2~n-3\ DPA~(A) Human monocytes (1 × 10^8^ cells/mL) were incubated with vehicle (PBS + 0.1% DMSO) or AUDA (25 μM) for 20 min (at room temperature). Cells were then incubated with either vehicle (PBS + 0.1% EtOH) or 16*S*,17*S*-ePD~n-3\ DPA~ (10 nM). Incubations were quenched after 15 min and products profiled using LM profiling. Results are mean ± SEM. n = 4 donors and two independent experiments. \*\*p \< 0.01 versus vehicle; \#p \<0.05 versus monocyte incubations.(B) 16*S*,17*S*-ePD~n-3\ DPA~ (10 nM) was incubated with human recombinant LTA~4~H (0.2 μM; Tris buffer). Incubations were quenched using ice-cold methanol and products identified using lipid mediator profiling. Left panel: MRM chromatogram *m/z* 361 \> 263 (arrow denotes expected retention time for PD1~n-3\ DPA~); right panel: MS-MS spectrum employed in the identification of 10,17*S*-hydroxy-7*Z*,11*E*,13*E*,15*E*,19*Z*-docosapentanenoic acid. Results are representative of n = 4 independent experiments.

Leukotriene A~4~ hydrolase (LTA~4~H) catalyses the hydrolysis of the allylic epoxide in LTA~4~ at the least sterically hindered carbon of the carbocation intermediate ([@bib34], [@bib35]) and is also expressed by human macrophages ([@bib33]). Therefore we questioned whether this enzyme was also responsible for catalyzing the conversion of 16*S*,17*S*-ePD~n-3\ DPA~ to PD1~n-3\ DPA~. LC/MS-MS analysis of products obtained when LTA~4~H was incubated with 16*S*,17*S*-ePD~n-3\ DPA~ gave four peaks that were identified as the non-enzymatic hydrolysis products of 16*S*,17*S*-epoxy-PD~n-3\ DPA~. The T~R~ and MS-MS spectra of peaks I and II corresponded to 10*R/S*,17*S*-dihydroxy-7*Z*,11*E*,13*E*,15*E*,19*Z*-docosapentaenoic acid, whereas peaks III and IV were identified as 16*R/S*,17*S*-dihydroxy-7*Z*,10*Z*,12*E*,14*E*,1*9Z*-docosapentaenoic acid ([Figure 5](#fig5){ref-type="fig"}B). For comparison LM profiling of the products obtained when LTA~4~H was incubated with LTA~4~ gave a major peak that eluted with a T~R~ of 13.6 min, with the MS-MS spectrum corresponding to LTB~4~ (n = 4 incubations).

Another epoxide hydrolase expressed by human macrophages, which is also involved in the catalysis of allylic epoxides to bioactive mediators, is epoxide hydrolase 2 (EPHX2) ([@bib14]). Thus, we next investigated whether this enzyme may play a role in the PD~n-3\ DPA~ biosynthetic pathway. Using flow cytometry we found that EPHX2 is expressed in monocytes and is upregulated during monocyte-to-macrophage differentiation ([Figure 6](#fig6){ref-type="fig"}A). Transfection of human monocytes with shRNA to EPHX2 led to a significant downregulation of PD2~n-3\ DPA~ and an increase in PD1~n-3\ DPA~ concentrations ([Figure 6](#fig6){ref-type="fig"}B). To further validate the role of EPHX2 in PD2~n-3\ DPA~ biosynthesis, we incubated hr-EPHX2 with 16*S*,17*S*-ePD~n-3\ DPA~, which gave a peak with T~R~ of 15.2 min and an MS-MS spectrum that corresponded to that of PD2~n-3\ DPA~ ([Figure 6](#fig6){ref-type="fig"}C). Of note, in these incubations we did not identify PD1~n-3\ DPA~, suggesting that this enzyme selectively catalyzed the conversion of 16*S*,17*S*-ePD~n-3\ DPA~ to PD2~n-3\ DPA~. Having found that hr-EPHX2 converted the epoxide to PD2~n-3\ DPA~, we next co-incubated hr-ALOX15 with hr-EPHX2 to obtain further evidence for the PD2~n-3\ DPA~ biosynthetic pathway in human cells. LM profiling of these incubations gave a peak with T~R~ and MS-MS spectrum corresponding to PD2~n-3\ DPA~ ([Figure 6](#fig6){ref-type="fig"}D). Of note, levels of this mediator in incubations with either hr-ALOX15 or EPHX2 were negligible. Similar findings were also made with incubations of hr-ALOX15B and EPHX2 (n = 3 distinct incubations). To further assess the role of EPHX2 in the biosynthesis of PD2~n-3\ DPA~ we incubated this enzyme with increasing concentrations of 16*S*,17*S*-ePD~n-3\ DPA~ and determined the reaction kinetics. Here we found that 16*S*,17*S*-ePD~n-3\ DPA~ was rapidly converted with a V~max~ of 3,439 ± 1,539 mmol/min and a K~M~ of 332 ± 188 μM ([Figure 6](#fig6){ref-type="fig"}E). Together these findings demonstrate that epoxide hydrolase enzymes are key in the conversion of 16*S*,17*S*-ePD~n-3\ DPA~ to PD1~n-3\ DPA~ and PD2~n-3\ DPA~, and identify EPHX2 as the enzyme responsible for the conversion of 16*S*,17*S*-ePD~n-3\ DPA~ to PD2~n-3\ DPA~.Figure 6EPHX2 Converts 16*S*,17*S*-ePD~n-3\ DPA~ to PD2~n-3\ DPA~ in Human Monocytes and Macrophages(A) Human monocytes were isolated and differentiated using GM-CSF (20 ng/mL), IFN-γ (20 ng/mL), and LPS (100 ng/mL) to produce M1 or M-CSF (20 ng/mL) and IL-4 (20 ng/mL) to obtain M2 cells and the expression of EPHX2 during the differentiation time course was evaluated using flow cytometry. Results are mean ± SEM. n = 4--6 donors per interval.(B) Human monocytes were transfected with shRNA to EPHX2 or CT shRNA (see the [STAR Methods](#sec5){ref-type="sec"} for details), cells were incubated for 10 hr at 37°C, then with *E. coli* for 45 min, and PD~n-3\ DPA~ concentrations evaluated using LM profiling. Results are mean ± SEM. n = 4 donors. \*p \< 0.05.(C) 16*S*,17*S*-ePD~n-3\ DPA~ (10 nM) was incubated with hrEPHX2 (0.2 μM; Tris buffer). Incubations were quenched using ice-cold methanol and products identified using lipid mediator profiling. Left panel*:* MRM chromatogram *m/z* 361 \> 233. Center panel*:* MS-MS spectrum employed in the identification of PD2~n-3\ DPA~. Right panel: PD2~n-3\ DPA~ concentrations. Results are representative of n = 4 independent experiments. \*p \< 0.01 versus EPHX2 incubations.(D) n-3 DPA (10 μM; Tris buffer) was incubated with hr-ALOX15 (0.2 μM), EPHX2 (0.2 μM), or a combination of the two enzymes. The incubations were quenched after 15 min and products extracted, identified, and quantified using lipid mediator profiling. Left panel: MRM chromatogram *m/z* 361 \> 233; right panel: PD2~n-3\ DPA~ concentrations. Results are representative of n = 4 independent experiments. Results for right panels in (C) and (D) are means ± SEM. \*p \< 0.01 versus EPHX2 incubations; \#p \< 0.01 versus ALOX15 incubations.(E) EPHX2 (0.2 μM, Tris buffer) was incubated with the indicated concentrations of 16S,17S-ePD~n-3\ DPA~. Incubations were quenched and PD2~n-3\ DPA~ concentrations were determined using lipid mediator profiling. Results are mean ± SEM. n = 3 independent experiments.

PD~n-3\ DPA~ Regulate Human Macrophage Phenotype and Responses {#sec2.4}
--------------------------------------------------------------

Having found that inhibition of the PD~n-3\ DPA~ pathway alters macrophage phenotype we next sought to determine the role of select members of the PD~n-3\ DPA~ pathway during monocyte-to-macrophage differentiation. Co-incubation of human macrophages with an ALOX15 inhibitor and either 16*S*,17*S*-ePD~n-3\ DPA~ or PD1~n-3\ DPA~ upregulated the expression of several lineage markers, including CD163 and CD64, when compared with cells incubated with the inhibitor alone ([Figure S5](#mmc1){ref-type="supplementary-material"}A). We next investigated whether the upregulation of these lineage markers was also associated with a restoration of the ability of human macrophages to clear apoptotic cells. Indeed, incubation of monocyte-dervied macrophages with 16*S*,17*S*-ePD~n-3\ DPA~ or PD1~n-3\ DPA~ rectified their ability to uptake apoptotic cells ([Figures S5](#mmc1){ref-type="supplementary-material"}B and S5C). These restorative actions of PD~n-3\ DPA~ on macrophage function were also retained *in vivo*, where administration of PD1~n-3\ DPA~ rectified the expression of lineage markers on both splenic and peritoneal macrophages from ALOX15^−/−^ mice ([Figures 7](#fig7){ref-type="fig"}A--7C; [Table S3](#mmc1){ref-type="supplementary-material"}). Furthermore PD1~n-3\ DPA~ also upregulated the ability of peritoneal macrophages from ALOX15^−/−^ mice to uptake apoptotic cells ([Figure 7](#fig7){ref-type="fig"}D) and bacteria ([Figure 7](#fig7){ref-type="fig"}E) *in vivo*. Together, these results demonstrate that the PD~n-3\ DPA~ pathway regulates key human macrophage functions in promoting the resolution of inflammation.Figure 7PD1~n-3\ DPA~ Rectifies Murine Resident Macrophage Phenotype and Function in ALOX15-Deficient Mice(A--C) The expression of phenotypic markers was assessed in peritoneal and splenic macrophages from ALOX15^−/−^ mice administered PD1~n-3\ DPA~ (10 ng/mouse for 7 days) or vehicle and WT mice using flow cytometry and macrophage phenotype interrogated using PLS-DA in (A) large peritoneal macrophages, (B) small peritoneal macrophages, and (C) splenic macrophages. Results are representative of n = 8 mice per group for (A and B) and n = 3--4 mice per group for (C).(D and E) Mice were treated as in (A--C), and on day 7 administered fluorescently labeled (D) apoptotic cells (6 × 10^6^ cells/mouse) or (E) *E. coli* (10^6^ CFU/mouse) via an intraperitoneal injection. Peritoneal cells were collected after 1 hr and phagocytosis was assessed in (D) CD64^+^ large peritoneal macrophages (left panel) and small peritoneal macrophages (right panel), and (E) total CD64^+^ macrophage population. Results are mean ± SEM. n = 8 mice per group for (D) and n = 4 mice per group for (E). \*p \< 0.05.(F) Structures are illustrated in most likely configurations based on biosynthetic evidence. The stereochemistries for PD1~n-3\ DPA~ and 16*S*,17*S*-PD~n-3\ DPA~ are established ([@bib1], [@bib2], [@bib9]).Related to [Figures S5](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

Herein, we established the PD~n-3\ DPA~ biosynthetic pathway and the role of this pathway in regulating key macrophage responses during monocyte-to-macrophage differentiation. Results from the present experiments demonstrate that, in human and mouse monocytes and macrophages, 15-lipoxygenases are the initiating enzyme in the PD~n-3\ DPA~ pathway catalyzing the formation of 17*S*-HpDPA and 16*S*,17*S*-ePD~n-3\ DPA~. The epoxide is then converted *via* enzymatic hydrolysis to PD1~n-3\ DPA~ and PD2~n-3\ DPA~, whereby the conversion of 16*S*,17*S*-ePD~n-3\ DPA~ to PD2~n-3\ DPA~ is catalyzed by EPHX2. Inhibition of ALOX15 activity led to a significant alteration in the expression of lineage markers as well as the ability of macrophages to uptake apoptotic cells and bacteria, actions that were recovered by either 16*S*,17*S*-ePD~n-3\ DPA~ or PD1~n-3\ DPA~.

During acute inflammation, monocytes are recruited to the site where under ideal conditions, they differentiate to macrophages with a tissue protective phenotype; a process that is central in the resolution of inflammation as well as tissue repair and regeneration ([@bib4], [@bib10]). Chronic, unresolved inflammation is associated with dysregulated monocyte differentiation leading to macrophages displaying a pro-inflammatory phenotype ([@bib10], [@bib28], [@bib40]). The mechanisms dictating whether monocytes differentiate into a tissue reparative or pro-inflammatory phenotype remain of interest. In the present study, we found that inhibiting ALOX15 expression and activity using both genetic and pharmacological approaches in mice and human primary cells dysregulated both macrophage phenotype and function ([Figure 1](#fig1){ref-type="fig"}). Incubation of monocytes throughout their differentiation into macrophages with either 16*S*,17*S*-ePD~n-3\ DPA~ or PD1~n-3\ DPA~ rescued the ability of macrophages to uptake apoptotic cells as well as upregulated the expression of lineage markers, including CD64 and CD163, which were decreased following ALOX15 inhibition. PD1~n-3\ DPA~ administration to ALOX15-deficient mice also rectified the expression of lineage markers on tissue-resident macrophages and the ability of peritoneal macrophages to uptake apoptotic cells and bacteria ([Figure 7](#fig7){ref-type="fig"}). Of note, ALOX15 is also the initiating enzyme in the RvD and LX biosynthetic pathway. Thus, while these results do not rule out the contribution of other ALOX15-derived pro-resolving mediators in the regulating monocyte-to-macrophage differentiation, they support a role for the PD~n-3\ DPA~ metabolome in regulating this process. The present findings also suggest that 16*S*,17*S*-ePD~n-3\ DPA~ is both a biosynthetic intermediate in the PD~n-3\ DPA~ pathway and exerts independent biological actions regulating cellular functions. These results are in line with findings made with other allylic epoxides including LTA~4~ ([@bib29]) and 13*S*,14*S*-epoxy-maresin ([@bib13]), which are also bioactive, regulating LM biosynthesis and cellular phenotype.

LMs are produced via the stereoselective conversion of essential fatty acids by their biosynthetic enzymes. Recent studies demonstrate that the differential regulation of the SPM biosynthetic enzymes may reflect disease status and contribute to the propagation of ongoing inflammation. In this context, for example, [@bib18] found that phosphorylation of the ALOX5 changes the product profile of the enzyme, whereby phospho-ALOX5 translocates to the nuclear membrane where it couples with phospholipase A~2~ and LTA~4~H to produce the potent leukocyte chemoattractant LTB~4~. In the absence of this phosphorylation the enzyme is found in the cytosol, where it couples with ALOX15, producing the tissue-protective and pro-resolving mediators RvD1 and LXA~4~ ([@bib18]). These mechanisms are linked with disease onset/progression whereby, in atherosclerosis, recent studies identified an increased expression of phosphorylated ALOX5 and a decrease in the RvD1 to LTB~4~ ratio in aortic lesions ([@bib17]). These results may also shed light on the apparently discordant results obtained with omega-3 supplementation. This is because, if the expression and/or subcellular localization of SPM biosynthetic enzymes is dysregulated, the product profile will be altered and the expected beneficial actions via SPM production may be diminished. Thus, furthering our understanding on the biosynthetic pathways governing SPM biosynthesis is essential in order to gain better insights into disease etiopathology. The present studies focus on establishing the role of the PD~n-3\ DPA~ in cells of the monocytic lineage. These findings demonstrate that human ALOX15 and ALOX15B catalyze the first two steps in the PD~n-3\ DPA~ biosynthetic pathway yielding an allylic epoxide. Using total organic synthesis, we established the absolute stereochemistry of this epoxide as 16*S*,17*S*-epoxy-7*Z*,10*Z*,1*2E*,14*E*,1*9Z*-docosapentaenoic acid. Furthermore, using this synthetic material we found that 16*S*,17*S*-ePD~n-3\ DPA~ was converted to PD1~n-3\ DPA~ and PD2~n-3\ DPA~ by different epoxide hydrolase enzymes, where in human cells EPHX2 was found to catalyze the conversion of 16*S*,17*S*-ePD~n-3\ DPA~ to PD2~n-3\ DPA~ ([Figure 7](#fig7){ref-type="fig"}). Of note, we also found that LTA~4~H was not involved in the biosynthesis of PD1~n-3\ DPA~.

In summation, the present findings establish the identity of enzymes involved in the PD~n-3\ DPA~ biosynthetic pathway, as well as the complete stereochemistry of the key intermediate in this pathway ([Figure 7](#fig7){ref-type="fig"}F). They also demonstrate that the PD~n-3\ DPA~ pathway plays a role in the differentiation of monocytes to macrophages, where inhibition of 15-lipoxygenase activity during monocyte-to-macrophage differentiation results in impaired monocyte-derived macrophage responses that are rescued by addition of PD~n-3\ DPA~. Thus, these findings establish candidates in understanding the etiopathology of inflammatory diseases as well as targets for patient stratification and essential fatty acid supplementation.

Significance {#sec4}
============

**Macrophages are central players in controlling the body's response to both sterile injury and infections. During the course of inflammation monocytes are recruited to the site of injury and/or infections, where they differentiate to macrophages. The phenotype displayed by these macrophages dictates whether the cells promote the termination of inflammation or lead to chronicity, with the mechanisms that control the monocyte-to-macrophage differentiation process remaining of interest. In the present study, we found that inhibition of ALOX15 activity during monocyte-to-macrophage differentiation reduced PD**~**n-3\ DPA**~ **production, altered human macrophage phenotype and their ability to clear dead cells, a key step in the termination of inflammation. Incubation of these cells with components of the PD**~**n-3\ DPA**~ **biosynthetic pathway rectified these responses. We established the identity and complete stereochemistry of 16*S*,*17S*-ePD**~**n-3\ DPA**~**, a key intermediate in this pathway, and the role of human 15-lipoxygenases in producing this intermediate. We also provide evidence for a role of epoxide hydrolase enzymes in catalyzing the conversion of this intermediate to the pro-resolving mediators PD1**~**n-3\ DPA**~ **and PD2**~**n-3\ DPA**~ **in human monocytes. Here we found that EPHX2 selectively catalyzes the conversion of 16*S*,17*S*-ePD**~**n-3\ DPA**~ **to PD2**~**n-3\ DPA**~**. Together these results establish the PD**~**n-3\ DPA**~ **pathway in human monocytes and the contribution of this pathway in monocyte-to-macrophage differentiation.**

STAR★Methods {#sec5}
============

Key Resources Table {#sec5.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**APC/Cy7 anti-human CD 14BiolegendClone 63D3;\
Cat \# 367107PE-Cy7 anti-human CD 32eBiosciencesClone 6C4;\
Cat \# 25-0329-41PE-Cy5 anti-CD 64AbcamClone 10.1;\
Cat \# ab192338Alexa Fluor 405 anti-ICAM-1NovusClone 1A29;\
Cat \# NBP2-22541Alexa Fluor anti-human 488 CD 68BiolegendClone Y1/82A;\
Cat \# 333811Brilliant Violet anti-human 650 CD 80BiolegendClone 2D10;\
Cat \# 305227PerCP-Cy5.5 anti-human CD 206BiolegendClone 15-2;\
Cat \# 321121PE-CF 594 mouse anti-human CD 163BD BiosciencesClone GHI/61;\
Cat \# 562670Monoclonal anti-ALOX15BSigmaClone 4A7\
Cat \# SAB1402114-100UGEPXH2 antibody \[2F2\]Gene TexCat \# GTX84567Alexa Fluor 488 Goat anti-mouse IgG (H + L)InvitrogenCat \# A11029Alexa Fluor 647 15-Lipoxygenase 1 rabbit polyclonalBiossCat \# bs-6505R-A647APC-Cy7 anti-mouse CD 64BiolegendClone X54-5/7.1\
Cat \# 139303PE anti-mouse CD 64 (FCγRI)BiolegendClone X54-5/7.1\
Cat \# 139303PE-Cy5 anti-mouse/human CD 11bBiolegendClone M1/70\
Cat \# 101210Brilliant Violet 650 rat anti-mouse I-A/I-E (MHC II)BiolegendClone M5/114.15.2\
Cat \# 107641APC-Cy7 rat anti-mouse F4/80BiolegendClone BM8\
Cat \# 123117BV785 hamster anti-mouse CD 11cBiolegendClone N418\
Cat \# 117336PerCP-eFluor710 rat anti-mouse TIM-4eBiosciencesClone 54 (RMT4-54)\
Cat \# 46-5866-28Alexa Fluor 488 COX 2Cell Signaling TechnologiesClone (D5H5) XP ®\
Cat \# 13596SPE-Dazzle 594 rat anti-mouse IL-10BiolegendClone JES5-16E3\
Cat \# 505034Brilliant Violet mouse anti-mouse 421 TGF-β1BiolegendClone TW7-16B4\
Cat \# 141407PE sheep anti-mouse Arginase 1R&DCat \# IC5868PAlexa Fluor 647 rabbit- anti-human iNOSNovusClone 4E5\
Cat \# NBP2-22119AF647TruStain Fc-blocking IgG (anti-mouse CD16/32)BiolegendClone 93\
Cat \# 101310**Bacterial and Virus Strains***Escherichia coli*Strain O6:K2:H1**Biological Samples**Leukocyte conesGBS Re NHS Blood/TransplantCat \# NC24**Chemicals, Peptides, and Recombinant Proteins**Ethanol, Absolute (200 proof), Mol Biology grade, Dnase, Rnase, Protease-freeFisher Scientific Uk LtdCat \# 10644795Methanol, Optima(TM) LC/MS gradeFisher Scientific Uk LtdCat \# 10767665Acetic acidFlukaCat \# 07692-1L-FMethyl formate, 98% for spectroscopyFisher Scientific Uk LtdCat \# 10414315n-Hexane; For HPLC; 97+%; Acros OrganicsFisher Scientific Uk LtdCat \# 11934421Deuterium-labelled 5S-HETECayman ChemicalsCat \# 10007276Deuterium-labelled Leukotriene (LT) B~4~Cayman ChemicalsCat \#: 320110Deuterium-labelled Lipoxin (LX) A~4~Cayman ChemicalsCat \#: 10007737Deuterium-labelled Resolvin (Rv) D2Cayman ChemicalsCat \#: 11184Deuterium-labelled prostaglandin (PG) E~2~Cayman ChemicalsCat \#: 314010PGD~2~Cayman ChemicalsCat \#: 10007202PGE~2~Cayman ChemicalsCat \#: 10007211PGF~2a~Cayman ChemicalsCat \# 16010Thromboxane B~2~Cayman ChemicalsCat \#: 10007237LTB~4~Cayman ChemicalsCat \#: 1000724020-OH-LTB~4~Cayman ChemicalsCat \# 20190LXA~4~Cayman ChemicalsCat \#: 10007271LXB~4~Cayman ChemicalsCat \#: 904205S,12S-diHETEIn-house biogenic synthesis (J Dalli)([@bib3])5S,15S-diHETECayman ChemicalsCat \#: 3528015-epi-LXA~4~Cayman ChemicalsCat \#: 9041515-epi-LXB~4~Custom Synthesis (Dr Charles Serhan, Harvard Medical School)([@bib6])RvE1Cayman ChemicalsCat \#: 10007848RvE2Custom synthesis([@bib37])RvE3Custom synthesis([@bib21])RvD1Cayman ChemicalsCat \#: 10012554RvD2Cayman ChemicalsCat \#: 10007279RvD3Cayman ChemicalsCat \#: 13834RvD4Custom Synthesis (Dr Charles Serhan, Harvard Medical School)([@bib43])RvD5Cayman ChemicalsCat \#: 10007280RvD6In-house biogenic synthesis (J Dalli)N/A17R-RvD1Cayman ChemicalsCat \#: 1306017R-RvD3Custom Synthesis (Dr Charles Serhan, Harvard Medical School)[@bib12]Maresin (MaR) 1Cayman ChemicalsCat \#: 10878MaR2Cayman ChemicalsCat \#: 163694S,14S-diHDHAIn-house biogenic synthesis (J Dalli)([@bib39])7S,14S-diHDHAIn-house biogenic synthesis (J Dalli)([@bib39])22-OH-MaR1In-house biogenic synthesis (J Dalli)([@bib7])14-oxo-MaR1In-house biogenic synthesis (J Dalli)([@bib7])Protectin (PD)1Custom Synthesis (Dr Charles Serhan, Harvard Medical School)([@bib30])10S,17S-diHDHACustom Synthesis (Dr Charles Serhan, Harvard Medical School)([@bib30])22-OH-PD1Custom Synthesis (Dr Trond V. Hansen, University of Oslo)([@bib42])n-3 DPACayman ChemicalsItem № 21907RvD1~n-3\ DPA~In-house biogenic synthesis (J Dalli)([@bib9])RvD2~n-3\ DPA~In-house biogenic synthesis (J Dalli)[@bib9]RvD5~n-3\ DPA~In-house biogenic synthesis (J Dalli)[@bib9]MaR1~n-3\ DPA~Custom Synthesis (Dr Trond V. Hansen, University of Oslo)([@bib41])7S, 14S-diHDPAIn-house biogenic synthesis (J Dalli)[@bib9]PD1~n-3\ DPA~Custom Synthesis (Dr Trond V. Hansen, University of Oslo)[@bib2]PD2~n-3\ DPA~In-house biogenic synthesis (J Dalli)[@bib9]16S, 17S-ePD~n-3\ DPA~Custom Synthesis (Dr Trond V. Hansen, University of Oslo)This paper10S,17S-diHDPAIn-house biogenic synthesis (J Dalli)[@bib9]Δ15trans-PD1~n-3\ DPA~In-house biogenic synthesis (J Dalli)This paper10epi-Δ15trans-PD1~n-3\ DPA~In-house biogenic synthesis (J Dalli)This paper17R-PD1Custom Synthesis (Dr Charles Serhan, Harvard Medical School)[@bib30]RvT1In-house biogenic synthesis (J Dalli)([@bib8])RvT2In-house biogenic synthesis (J Dalli)[@bib8]RvT3In-house biogenic synthesis (J Dalli)[@bib8]RvT4In-house biogenic synthesis (J Dalli)[@bib8]Histopaque -- 1077SigmaCat \# 10771-100MLDulbecco's phosphate buffer saline with MgCl~2~ and CaCl~2~ (PBS^+/+^)SigmaCat \# D8662Dulbecco's phosphate buffer saline without MgCl~2~ and CaCl~2~ (PBS^-/-^)SigmaCat \# D8537RPMI-1640SigmaCat \# R8758RPMI 1640 Medium, no glutamine, no phenol redGibco/Life TechnologiesCat \# 32404014Recombinant Human M-CSFR&DCat \# 216-MC-025PD146176Cambridge BioscienceCat \# 10010518Human serum type AB (male)SigmaCat \# H4522-100MLPenicillin-StreptomycinSigmaCat \# P4333Fetal bovine serum (FBS)Gibco/Life TechnologiesCat \# 105000-64DMSO, cell culture reagentChemCruzCat \# sc-358801Bovine serum albumin (BSA)SigmaCat \# A9418EDTAInvitrogenCat \# 15575-038PKH26 Red Fluorescent Cell Linker kitSigmaCat \# PKH26GL-1KTPKH67 Green Fluorescent Cell Linker kitSigmaCat \# PKH67GL-1KTTrypan BlueSigmaCat \# T8154Polybrene Transfection ReagentMillipore, UK LtdCat \# TR-1003-GRecombinant Human GM-CSFBiolegendCat \# 572902Human recombinant INF-γBiolegendCat \# 570206Human recombinant IL-4BiolegendCat \# 574002LipopolysaccharidesSigmaCat \# L2630ALOX15 Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector (Gene ID = 246). 5μg purified plasmid DNA per constructOriGENETL314822MISSION shRNA Bacterial Clone ALXO15BSigmaCat \#s SHCLNG - TRCN0000432221, TRCN0000056583, TRCN0000056584, TRCN0000056585, TRCN0000056586MISSION shRNA Bacterial Glycerol Stock EPHX2SigmaCat \#s SHCLNG - TRCN0000050553, TRCN0000050554, TRCN0000050555, TRCN0000050556, TRCN0000050557MISSION® pLKO.1-puro Empty Vector Control Plasmid DNASigmaCat \# SHC001Trizma hydrochlorideSigmaCat \# T3253hr-ALOX15Novus BiologicalsCat \# H00000246-P01hr-ALOX15BCayman ChemicalsCat \# 10011263-100ug-CAYhr-EPHX2Cayman ChemicalsCat \# 10011669AUDASigmaCat \# SML01774% PFA solutionAffymetrixCat \# 19943Permeabilization buffer (10X)eBiosciencesCat \# 00-8333-56Fixation/Permeabilization ConcentrateeBiosciencesCat \# 00-5123-43Fixation/Permeabilization DiluenteBiosciencesCat \# 00-5223-56Hanks Balanced Salt solutionSigmaCat \# H6648γ-Globulins from human blood (FC block)SigmaCat \# G4386-5GLIVE/DEAD BacLight Bacterial Viability dyeMolecular Probes, Life TechnologiesCat \# B35000**Critical Commercial Assays**APC Annexin V Apoptosis Detection Kit with PIBiolegendCat \# 640932EasySep™ Human Monocyte Isolation KitStemCell TechnologiesCat \# 19319**Experimental Models: Organisms/Strains**Mus musculus, NCBI Taxonomy ID:[10090](ncbi-tnm:10090){#intref0010},\
C57BL/6/FVBCharles RiverJAX™ C57BL/6JMus musculus, NCBI Taxonomy ID:[10090](ncbi-tnm:10090){#intref0015},\
C57BL/6/FVB 12/15-LOX KOThe Jackson LaboratoryB6.129S2-*Alox15*^*tm1Fun*^/J\
Stock \# 002778**Experimental Models: Cell lines**HL-60ATCCCat \# CCL-240**Software and Algorithms**FlowJo softwareTree Star, Ashland, OR<https://www.flowjo.com/solutions/flowjo/downloads>GraphPad Prism 6.0fGraphPad Software, CA<https://www.graphpad.com/support/prism-6-updates/>SIMCA 14.1 softwareUmetrics, Umea, Sweden<https://umetrics.com/kb/simca-141>IDEAS® (Image Data Exploration and Analysis Software, Version 6.0)Amnis®, EMD Millipore<http://www.merckmillipore.com/GB/en/life-science-research/cell-analysis-flow-cytometry/amnis-imaging-flow-cytometers/analysis-acquisition-software/ideas-software/qe2b.qB.Oq8AAAFLQM8Jx34R,nav>**Other**Isolute 500 mg / 3ml C18 SPE columnBiotage, SwedenCat \# 220-0050-BPoroshell 120 EC-18 4.6 mm ×100 mm × 2.7 μm reversed phase columnAgilent, USAN/ALSR Fortessa cell analyserBD Biosciences, UKN/AExtra-HeraBiotage, SwedenN/ATurboVap LVBiotage, SwedenN/AQtrap 5500/6500AB SciexN/AShimadzu SIL-20AC auto-injectorShimadzu Corp.N/ALC-20AD Binary pumpShimadzu Corp.N/AFLUOstar Omega microplate readerBMG LabtechN/AImageStream X MK2 Imaging Flow CytometerAmnis®, EMD MilliporeN/A

Contact for Reagent and Resource Sharing {#sec5.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jesmond Dalli (<j.dalli@qmul.ac.uk>).

Experimental Model and Subject Details {#sec5.3}
--------------------------------------

### Animal Studies {#sec5.3.1}

Healthy 6-11 week old male C57/Black6 wild type mice (Charles River) and ALOX15^-/-^ (The Jackson Laboratory) mice were used in the reported studies. The experiments strictly adhered to UK Home Office regulations (Guidance on the Operation of Animals, Scientific Procedures Act, 1986) and Laboratory Animal Science Association (LASA) Guidelines (Guiding Principles on Good Practice for Animal Welfare and Ethical Review Bodies, 3rd Edition, 2015). Animals were kept on a 12 h light dark cycle, with lights turned on at 7:00 h and lights turned off at 19:00h under specific pathogen free housing and had access to food and water *ad libitum*. Sample size was based on the statistical analysis of previous experiments and no mice were excluded. Animals were randomly assigned to control and experimental groups. The investigators were not blinded to group assignments.

### Human Primary Cells {#sec5.3.2}

Healthy human peripheral blood mononuclear cells (PBMCs) were isolated from leukocyte cones obtained from the NHS Blood and Transplant bank and experiments were conducted in accordance with a protocol approved by Queen Mary Research Ethics Committee (QMREC 2014:61) and in accordance with the Helsinki declaration. Informed consent was obtained from all volunteers. Given that cones were obtained from the NHS Blood and Transplant bank and volunteers were unidentified, no information was available on sex, age, their involvement in previous experiments or if they were drug or test naïve. Primary cells were incubated for at 37°C at 5 % CO~2~. The HL60 cell line was established in a female donor.

Method Details {#sec5.4}
--------------

### Monocyte Incubations {#sec5.4.1}

Human PBMCs were isolated from healthy human volunteers purchased from the NHS Blood and Transplant bank and experiments conducted in Queen Mary Research Ethics Committee approval (QMREC 2014:61) and the Helsinki declaration. Here blood cones were used and PBMCs were isolated by density centrifugation where cells were layered on to Histopaque - 1077 (Sigma) and centrifuged for 30 minutes at 400 x g at room temperature (RT). Macrophages were prepared using published protocols ([@bib11]) where PBMCs were plated into 10 cm tissue culture plates and incubated at 37°C for 30 min in PBS^+/+^. Non-adherent cells were then removed by adding PBS^-/-^ and washed vigorously. Adherent cells (3 × 10^7^ cells/incubation) were then incubated with vehicle (PBS+0.1% ethanol), 1 nM 16*S*,17*S*-ePD~n-3\ DPA~ or 1 nM PD1~n-3\ DPA~ in RPMI 1640 (Sigma) for 30 minutes at 37°C. These were then incubated with either vehicle or ALOX15 inhibitor (10 μM PD146176 ([@bib36]); Cambridge Bioscience) in RPMI 1640 containing 10% human serum, 1% Penicillin-Streptomycin and 20 ng/mL M-CSF. The cells were incubated for 3 days at 37°C at 5% CO~2~ and the media together with mediators and inhibitors were added as above and the cells were incubated a further 4 days. For lipid mediator profiling of cell supernatant, RPMI 1640 Medium (no glutamine) with no phenol red was used. Cell supernatants were collected and placed in two volumes of methanol containing deuterium labelled internal standards (500 pg of d~4~-Prostaglandin (PG)E~2~, d~5~-LXA~4~, d~4~-RvD2, d~4~-Leukotriene (LT)B~4~ and d~8~-5*S*-Hydroxy-eicosatetraneoic acid; Cayman Chemicals). These were stored at -20°C until extraction (see below). In select experiments to obtain M1 macrophages adherent cells were cultured with GM-CSF (20ng/mL) for 6 days then with LPS (1ng/mL) and interferon-γ (20ng/mL) for 24h. To obtain M2 macrophages adherent cells where incubated with M-CSF (20ng/mL) for 7 days then with IL-4 (20ng/mL) for 48 h. In all cases the purity of the cell preparations ranged between 90-95%.

For human monocyte incubations we isolated monocytes from PBMCs using the EasySep™ Human Monocyte Isolation Kit, following manufacturer's instruction where the purity of the resultant cell population was of ∼95%. Human monocytes (1 × 10^8^ cells/mL) were incubated with n-3 DPA (10μM) and *Escherichia coli* (5 × 10^9^ CFU/mL) in PBS at 37°C. Incubations were quenched using excess acidified methanol (apparent pH ∼3) containing deuterium labelled d~4~-LTB~4~ and products were extracted as detailed below.

In select experiments monocytes (1x10^8^ cells/ml) were incubated with vehicle (PBS + 0.01% DMSO) or 12-\[\[(tricyclo\[3.3.1.13,7\]dec-1-ylamino)carbonyl\]amino\]-dodecanoic acid (AUDA; 25μM) for 20 min at RT. Cells were then incubated with either vehicle (PBS + 0.1%EtOH) or 16*S*,17*S*-e-PD~n-3\ DPA~ (10nM) for 15 min. Incubations were then quenched and products identified and profiled using LM profiling as detailed below.

Monocytes (1.5x10^6^ cells/ml) were suspended in phenol red free RPMI 1640 containing 10% human serum, 8μg/ml of polybrene and 50ng/ml of shRNA to ALOX15B or CT shRNA. The cell suspension was then centrifuged at 1000 x g for 90 min at 4°C. Cells were then plated and incubated for a further 12h at 37°C. Monocytes were then detached after 5 minutes incubation in 2mM EDTA in PBS^-/-^, and the expression of ALOX15B was evaluated using flow cytometry. Cells were also suspended in PBS containing 0.1% human serum and incubated with *E. coli* (1:50 monocytes to bacteria) for 45 min at 37°C. Incubations were quenched using two volumes of ice-cold methanol and products profiled using lipid mediator profiling.

In separate experiments monocytes were plated in 6 well plates and incubated with phenol red free RPMI 1640 containing 10% human serum, 8μg/ml of polybrene and 2μg/ml of shRNA to ALOX15, EPHX2 or CT shRNA. The cell incubations were gently mixed for the first 5 hours, media was then removed and cells incubated with 15% DMSO in Hanks' Buffered Saline Solution for 4 mins at 37°C. The solution was then removed, cells were rinsed with PBS and then incubated for a further 7h in phenol red free RPMI containing 10% human serum and 1% Penicillin-Streptomycin. Cells were then detached after 5 minutes incubation in 2mM EDTA in PBS^-/-^, and expression of ALOX15 and EPHX2 was evaluated using flow cytometry. Cells were also suspended in PBS containing 0.1% human serum and incubated with *E. coli* as detailed above.

Mouse monocytes were isolated by adhesion of bone marrow cell suspension from WT and ALOX15-deficient mice to tissue culture dishes. After 45 min cell were detached and cell populations determined to be ∼80-90% monocytes. Monocytes (2 × 10^6^ cells/mL) were incubated in phenol red free RPMI containing 0.1% FBS and *E. coli* (1 × 10^8^ CFU/mL) at 37°C for 45 min. Incubations were quenched using 2 volumes of ice-cold methanol containing deuterium labelled internal standards and lipid mediators identified and quantified using lipid mediator profiling.

### Enzyme Incubations {#sec5.4.2}

Human recombinant (hr)-ALOX15 (0.2μM; Novus Biologicals) or (hr)-ALOX15B (0.2μM; Cayman Chemicals) was incubated with n-3 DPA (10 μM) in Tris buffer (pH = 8.0) at RT for 2 min. Products were quenched using excess acidified methanol (apparent pH ∼3) containing deuterium labelled d~4~-LTB~4~ and extracted as detailed in the lipid mediator profiling section below. In select incubations hr-ALOX15 or hr-ALOX15B were incubated with EPHX2 (0.2μM; Cayman Chemicals) and n-3 DPA (10μM) in Tris buffer (pH = 8.0) at RT for 15 min. Incubations were quenched using ice-cold methanol and products extracted, identified and quantified as detailed below.

In select incubations EPHX2 (0.2μM) was incubated with 16*S*,17*S*-ePD~n-3\ DPA~ (10nM) in Tris buffer (pH = 8.0) at RT for 10 min; incubations were then quenched, and products identified and quantified as detailed below.

### Flow Cytometry {#sec5.4.3}

Flow cytometry was used to determine the phenotypic lineage of the monocyte-derived macrophages using fluorescently conjugated antibodies. Cells were fixed in 1% paraformaldehyde (4% paraformaldehyde in PBS^-/-^) for 10 minutes at room temperature. Cells were incubated with the following antibodies in a 1:100 dilution for 30 minutes at 4°C in staining solution (1:1 PBS with 0.02 % BSA and FC block): APC/Cy7 anti-human CD14 (clone 63D3, Biolegend), PE-Cyanine7 anti-human CD32 (clone 6C4, eBiosciences), Alexa Fluor (AF) 405 anti-ICAM-1 (clone 1A29, Novus), PE/Cy5 anti-CD64 (clone 10.1, Abcam), AF 488 anti-human CD68 (clone Y1/82A, Biolegend), Brilliant Violet (BV) 650 anti-human CD80 (clone 2D10, Biolegend), PerCP/Cy5.5 anti-human CD206 (clone 15-2, Biolegend) and PE-CF594 anti-human CD163 (clone GHI/61, BD Biosciences). LSR Fortessa cell analyser (BD Biosciences) was used to perform multiparameter analysis, followed by analysis using FlowJo (Tree Star Inc., V10).

To determine the expression of PD~n-3\ DPA~ biosynthetic enzymes, monocytes and macrophages were incubated with M-CSF and IL-4 or GM-CSF, IFNγ and LPS for 7 days as detailed above. At the indicated intervals cells were collected, permeabilized using eBiosciences Fixation/ Permeabilization Solution Kit following manufacturer's instructions, non-specific binding was quenched using non-specific IgG (16mg/mL) and cells were then incubated with rabbit anti-human 15-LOX type 1, mouse anti-human 15-LOX type 2, and mouse anti-human EH2 for 30 min at 4°C. To determine the expression of 15-LOX type 2 and EH2, cells were then incubated with AF 488 goat anti-mouse IgG for 30 min at 4°C and staining evaluated using LSR Fortessa cell analyser (BD Biosciences) was used to perform multiparameter data acquisition, followed by analysis using FlowJo (Tree Star Inc., V10).

In select experiments cells were collected from the peritoneum of WT and ALOX1- deficient mice by lavaging the peritoneum with PBS. Splenic cells were obtained following dissociation of spleens from WT and ALOX15-deficient mice using a 70 μM filter. The cells were counted and incubated with the following antibodies in a 1:100 dilution for 30 minutes at 4°C in staining solution (1:1 PBS with 0.02 % BSA and TrueStain FC Blocking IgG): PE-Cy5 anti-mouse/human CD 11b (Clone M1/70, Biolegend), BV 650 rat anti-mouse I-A/I-E (MHC II) (Clone M5/114.15.2, Biolegend), APC-Cy7 rat anti-mouse F4/80 (Clone BM8, Biolegend), BV785 hamster anti-mouse CD 11c (Clone N418, Biolegend) and PerCP-eFluor710 rat anti-mouse TIM-4 (Clone 54 (RMT4-54), eBiosciences). For intracellular staining, cells were permeabilized using eBiosciences Fixation/ Permeabilization Solution Kit following manufacturer's instructions for 20 min at RT and then with fluorescently labelled antibodies in a 1:50 dilution for 30 minutes at 4°C in staining solution (1:10 Permeabilization buffer (10X) (eBiosciences) and PBS with 0.02 % BSA): AF 488 COX 2 (Clone (D5H5) XP ®, Cell Signaling Technologies), PE-Dazzle 594 rat anti-mouse IL-10 (Clone JES5-16E3, Biolegend), BV 421 mouse anti-mouse TGF-β1 (Clone TW7-16B4, Biolegend), PE sheep anti-mouse Arginase 1 (Cat \# IC5868P, R&D) and AF 647 rabbit- anti-human iNOS (Clone 4E5, Novus). Non-specific binding was quenched using TruStain Fc-blocking IgG (anti-mouse CD16/32) and the staining was evaluated as above. For cells obtained from both *in vivo* efferocytosis and phagocytosis experiments non-sepcific binding was quenched as detailed above. Cells were then incubated in PBS^-/-^ containing 0.02% BSA and either APC-Cy anti-mouse CD64 or PE anti-mouse CD64 (at 1:100 dilution) for 30 min at 4^o^C and staining evaluated.

### Macrophage Incubations {#sec5.4.4}

#### *In Vitro* Efferocytosis {#sec5.4.4.1}

Macrophages, prepared as described above, were seeded into 96 well plates at 5 × 10^4^ cells per well in RPMI 1640 medium with 10 % human serum at 37°C. Apoptotic cells were prepared by incubating the human promyelocytic leukemic cell line HL60 at 70°C for 2h yielding ∼60% Annexin V positive / propidium iodide negative cells and 35% Annexin V positive / propidium iodide positive cells using APC Annexin V Apoptotic Detection Kit with PI (Biolegend). These were then stained using PKH26 Red Fluorescent Cell Linker kit (Sigma) following manufacturer's instructions and efferocytosis was assessed as in ([@bib11]). In brief, fluorescently labelled apoptotic cells (1:3, macrophages to apoptotic cells) were added to the macrophages and incubated at 37°C for 45 minutes. Cells were washed with PBS and extracellular fluorescence was quenched using trypan blue (1:15 in PBS). Fluorescence was then measured using a FLUOstar Omega microplate reader (BMG Labtech). In select experiments apoptotic cells were labelled using PKH67 and incubated with macrophages as detailed above. Macrophage efferocytosis was then evaluated using an ImageStream X MK2 and analysis was performed using IDEAS® (Image Data Exploration and Analysis Software, Version 6.0).

#### *In Vivo* Efferocytosis {#sec5.4.4.2}

Mice were administered either vehicle or PD1~n-3\ DPA~ (10ng/mouse) via i.p. injection for 7 days. Apoptotic cells were prepared and labelled as detailed above using PKH67 dye. These (6x10^6^ cells per mouse) were injected via intraperitoneal injection to WT and ALOX15-deficient mice. After 1h cells were collected by peritoneal lavages and incubated with an APC-Cy7 labelled anti-mouse CD64 antibody as detailed above and efferocytosis in CD64 positive macrophages was evaluated using Flow cytometry.

#### *E. coli* Incubations {#sec5.4.4.3}

Macrophages (2x10^6^ cells) were incubated with *E. coli* (1x10^7^ cells) for 30 minutes at 37°C. Incubations were quenched using two volumes of ice-cold methanol containing deuterium labelled internal standards (500 pg each of d~4~-PGE~2~, d~5~-LXA~4~, d~4~-RvD2, d~4~-LTB~4~ and d~8~-5S-HETE, Cayman Chemicals). Samples were then stored at -20°C prior to extraction and lipid mediator profiling.

#### In Vivo Phagocytosis {#sec5.4.4.4}

Mice were administered either vehicle or PD1~n-3\ DPA~ (10ng/mouse) via i.p. injection for 7 days. *E. coli* were labelled using LIVE/DEAD BacLight Bacterial Viability dye following manufacturer's instructions. Fluorescently labelled bacteria were then injected *via* intraperitoneal injection to WT and ALOX15-deficient mice and peritoneal lavages were collected after 1h. Cells were stained using fluorescently labelled PE anti-mouse CD64 antibody and bacterial phagocytosis was evaluated using flow cytometry as detailed above.

### Lipid Mediator Profiling {#sec5.4.5}

Proteins were allowed to precipitate by keeping samples at -20°C for 30 minutes. Deuterium-labelled standards, d~4~-PGE~2~, d~5~-LXA~4~, d~4~-RvD2, d~4~-LTB~4~ and d~8~-5S-HETE were used to aid in identification and quantification of lipid mediators ([@bib11]). Following protein precipitation, samples were then extracted using an ExtraHera (Biotage) with ISOLUTE C18 columns (500 mg, 3 mL; Biotage). This involved the conditioning of the Solid-phase ISOLUTE C18 500 mg/3 mL columns with methanol for 60 seconds using 2.5 bar positive pressure. Samples, brought to 10 mL with pH 3.5 water, were loaded onto the columns for 90 seconds using 2.5 bar positive pressure. The acid in the C18 columns was neutralised by washing the columns with 2 mL pH 7 water for 45 seconds using 2.5 bar positive pressure, followed by the hexane wash to elute hydrophobic molecules. This was done four times with 3 mL hexane using 2.5 bar positive pressure for 60 seconds for each wash. Mediators were then eluted into collection tubes with the addition of 5 mL methyl formate at 1.5 bar positive pressure for 120 seconds. Products were brought to dryness using a gentle nitrogen stream and TurboVap LV (Biotage), these were then suspended in phase containing methanol and water, 1:1 (vol/vol).

An LC-MS-MS system, comprising of a Qtrap 5500 (AB Sciex) or Qtrap 6500 plus (AB Sciex), Shimadzu SIL-20AC autoinjector, LC-20AD binary pump (Shimadzu Corp.) and Agilent C18 Poroshell column (150 mm × 4.6 mm × 2.7 μm) was used to profile lipid mediators. The gradient was initiated at 20:80:0.01 (vol/vol/vol) methanol/water/acetic acid for 0.2 mins this was ramped to 50:50:0.01 (vol/vol/vol) over 12 seconds, maintained for 2 minutes, then ramped to 80:20:0.01 (vol/vol/vol) over 9 minutes, and maintained for 3.5 minutes. The ratio was then ramped to 98:2:0.01 (vol/vol/vol) for 5.5 minutes. The flow rate was kept at 0.5 mL/minute throughout.

Mediator concentrations were determined using multiple reaction monitoring (MRM) using signature parent ion (Q1) and characteristic daughter ion (Q3) pairs. A minimum of six diagnostic ions were used to confirm their identities, using published criteria ([@bib11]). The peak area of the MRM transition and linear calibration curves with an r^2^ value of 0.98 to 0.99 were used to quantify each of the molecules. The detection limit was ∼0.1 pg.

### Total Organic Synthesis of 16*S*,17*S*-ePD~n-3\ DPA~ {#sec5.4.6}

Unless stated otherwise, all commercially available reagents and solvents were used in the form they were supplied without any further purification. The stated yields are based on isolated material. All reactions were performed under an argon atmosphere using Schlenk techniques. Reaction flasks were covered with aluminium foil during reactions and storage to minimize exposure to sunlight. Thin layer chromatography was performed on silica gel 60 F254 aluminium-backed plates fabricated by Merck. Flash column chromatography was performed on silica gel 60 (40-63 μm) produced by Merck. NMR spectra were recorded on a Bruker AVI600, Bruker AVII400 or a Bruker DPX300 spectrometer at 600 MHz, 400 MHz or 300 MHz respectively for ^1^H NMR and at 150 MHz, 100 MHz or 75 MHz respectively for ^13^C NMR. Coupling constants (*J*) are reported in hertz and chemical shifts are reported in parts per million (δ) relative to the central residual protium solvent resonance in ^1^H NMR (CDCl~3~ = δ 7.26, DMSO-*d*~*6*~ = δ 2.50, benzene-*d*~*6*~ = δ 7.16 and MeOD-*d*~*4*~ = δ 3.31 ppm) and the central carbon solvent resonance in ^13^C NMR (CDCl3 = δ 77.00, DMSO-*d*~*6*~ = δ 39.43, benzene-*d*~*6*~ = δ 128.06 and MeOD-*d*~*4*~ = δ 49.00 ppm). Mass spectra were recorded at 70 eV on Micromass Prospec Q or Micromas QTOF 2W spectrometer using EI, ES or CI as the methods of ionization. High resolution mass spectra were recorded on Micromass Prospec Q or Micromas QTOF 2Wspectrometer using EI or ES as the methods of ionization. Optical rotations were measured using a 0.7 mL cell with a 1.0 dm path length on an Anton Paar MCP 100 polarimeter. HPLC analyses were performed on an Agilent Technologies 1200 Series instrument with diode array detector set at 254 nm and equipped with a C18 stationary phase (Eclipse XDB-C18 5 μm 4.6 × 150 mm), applying the conditions stated. GLC analyses were performed on an Agilent 7820A with a FID detector, HP-5 capillary column, with helium as the carrier gas and by applying the conditions stated.

#### Synthesis of methyl (7Z,10Z,12E,14E)-15-((2S,3S)-3-((Z)-pent-2-en-1-yl)oxiran-2-yl)pentadeca-7,10,12,14-tetraenoate (methyl ePD1~n-3\ DPA~) {#sec5.4.6.1}

The epoxy aldehyde (2*E*,4*E*)-5-((2*S*,3*S*)-3-((*Z*)-pent-2 en-1-yl)oxiran-2-yl)penta-2,4-dienal was prepared from commercially available 2-(triphenyl-λ^5^-phosphanylidene)acetaldehyde and (2*R*,3*S*)-3-((*Z*)-pent-2-en-1-yl)oxirane-2-carbaldehyde as described ([@bib1]). The Wittig-salt methyl (*Z*)-10-(iodotriphenyl-λ^5^-phosphanyl)dec-7-enoate was made according to literature protocols ([@bib32])

#### Z-Selective Wittig Reaction {#sec5.4.6.2}

This reaction was performed as earlier reported ([@bib2]). In brief, 1.3 equiv. of the Wittig salt methyl (*Z*)-10-(iodotriphenyl-λ^5^-phosphanyl)dec-7-enoate was dissolved in THF and then HMPA was added. This solution was cooled to −78°C. Then NaHMDS (0.60 M in toluene, 1.3 equiv.) was added drop-wise. The reaction mixture was stirred for 30 min at this temperature. The epoxy aldehyde (2*E*,4*E*)-5-((2*S*,3*S*)-3-((*Z*)-pent-2 en-1-yl)oxiran-2-yl)penta-2,4-dienal (1.0 equiv.) was azeotroped twice with 2-methyltetrahydrofuran, then dissolved in THF, and cooled to −78°C. This solution was added dropwise to the reaction flask via cannula and the resulting reaction mixture was stirred for 1 h at −78°C. Then the temperature of the reaction mixture was quickly warmed to −20°C and kept at this temperature for a few minutes. The reaction mixture was then quenched by the addition of an equal amount of phosphate buffer (0.2 M, pH = 7) as the volume of the reaction mixture. The phases were separated, and the aqueous phase was extracted with Et~2~O. The combined organic layers were dried with Na~2~SO~4~, then filtrated, and concentrated in vacuo. The resulting oil was purified by silica gel chromatography that had been deactivated by a solution containing Et~3~N (3%), Et~2~O (20%) in heptane. The product was eluted with Et~2~O (25%) in heptane to provide the titled epoxy methyl ester as a colorless oil. Physical and spectral data: \[α\]^20^~D~ = −38 (c = 0.20, CHCl~3~); UV (hexane) λ~max~ 270, 281, 292; ^1^H NMR (600 MHz, benzene-*d*~*6*~) δ 6.54 (dd, *J* = 14.7, 11.4 Hz, ^1^H), 6.39 (dd, *J* = 15.3, 10.8 Hz, ^1^H), 6.11 (dd, *J* = 14.8, 10.9 Hz, ^1^H), 6.04 (t, *J* = 11.2 Hz, ^1^H), 5.51 -- 5.31 (m, ^6^H), 3.36 (s, ^3^H), 3.06 (dd, *J* = 7.8, 1.8 Hz, ^1^H), 2.91 (t, *J* = 7.1 Hz, ^2^H), 2.71 (td, *J* = 5.2, 2.0 Hz, ^1^H), 2.24 (dq, *J* = 13.8, 6.4 Hz, ^1^H), 2.20 -- 2.14 (m, ^1^H), 2.09 (t, *J* = 7.4 Hz, ^2^H), 1.94 (dq, *J* = 23.1, 8.4, 7.5 Hz, ^4^H), 1.53 (p, *J* = 7.4 Hz, ^2^H), 1.25 -- 1.13 (m, 4H), 0.88 (t, *J* = 7.5 Hz, ^3^H). ^13^C NMR (151 MHz, C~6~D~6~) δ 173.3, 134.7, 134.1, 132.3, 131.4, 131.4, 130.8, 129.0, 128.9, 127.6, 123.2, 60.3, 57.7, 51.0, 34.1, 30.1, 29.6, 29.0, 27.4, 26.7, 25.2, 21.0, 14.4; HRMS (TOF ES^+^): Exact mass calculated for C~23~H~34~O~3~Na \[M+Na\]^+^: 381.2400, found 381.2400. TLC (heptane/Et~2~O, 74:26 CAM stain): *R*~*f*~ = 0.21.

(7Z,10Z,12E,14E)-15-((2S,3S)-3-((Z)-pent-2-en-1-yl)oxiran-2-yl)pentadeca-7,10,12,14-tetraenoic acid (ePD~n-3\ DPA~). Methyl (7Z,10Z,12E,14E)-15-((2S,3S)-3-((Z)-pent-2-en-1-yl)oxiran-2-yl)pentadeca-7,10,12,14-tetraenoate (100 μg in hexane/Et~2~O) was dried under a gentle stream of nitrogen and then dissolved in 500 μL of THF. For additional details on the preparation of this compound, see ([@bib32]). This THF solution was cooled to -78°C using a dry ice/isopropanol cooling bath. Then 100 μL of aqueous 1.0 M LiOH solution was slowly added via a Hamilton syringe at -78°C. Additional 100 μL of H~2~O was added and the vial was covered with aluminium foil and left stirring for 10 h. The solution above the precipitated lithium salt was gently removed by using a syringe. Next, the THF-solution was dried under a gentle stream of nitrogen before quantification using UV (hexane) λ~max~ 271 (log ε 3.58), 280 (log ε 4.08), 298 (log ε 2.69) nm. After quantification and removal of hexane, the acid was suspended in 50 μL PBS^+/+^ pH = 7.45. The PBS solution was kept on solid dry ice in a closed container prior to use, and was used for incubation biological experiments. The structure of the chemical labile free acid was determined indirectly by using UV and LC/MS-MS experiments.

Quantification and Statistical Analysis {#sec5.5}
---------------------------------------

Results are represented as mean ± SEM. Differences between groups were assessed using one-sample t test (normalized data), Student's t test (2 groups), 1-way ANOVA (multiple groups) followed by post hoc Dunnett's test using GraphPad Prism 6 software. Investigators were not blinded to group allocation or outcome assessment. The criterion for statistical significance was P ≤ 0.05. Sample sizes for each experiment were determined on the variability observed in prior experiments ([@bib10]) and preliminary experiments. Partial least squares-discrimination analysis (PLS-DA) and principal component analysis (PCA) ([@bib22]) were performed using SIMCA 14.1 software (Umetrics, Umea, Sweden) following mean centering and unit variance scaling of LM levels. PLS-DA is based on a linear multivariate model that identifies variables that contribute to class separation of observations on the basis of their variables (LM levels). During classification, observations were projected onto their respective class model. The score plot illustrates the systematic clusters among the observations (closer plots presenting higher similarity in the data matrix). Loading plot interpretation identified the variables with the best discriminatory power (Variable Importance in Projection greater than 1) that were associated with the distinct intervals and contributed to the tight clusters observed in the Score plot.

Data and Software Availability {#sec5.6}
------------------------------

Data are available upon request to the Lead contact.
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